Steven D. Maslowski
Partner
Areas of Focus
- Patent Litigation
- Intellectual Property
- Life Sciences Intellectual Property
- Inter Partes Review
- Trade Secret Litigation
- IP Transactions
- ITC Section 337 Investigations
- Supreme Court & Appellate: IP
- Health Care & Life Sciences
- Technology
- SEP/FRAND Disputes
- Lead trial lawyer who litigates patent infringement disputes in the life sciences.
- Cases have involved highly-complex biological and chemical inventions, as well as medical devices.
- Leads the firm’s intellectual property practice.
Steve works with life sciences companies in major patent litigation involving leading-edge health care treatments. He has been a leader on trial teams for some of the biggest cases in the biotechnology and medical device fields. He also represents clients in matters involving trade secret, tortious interference, trademark and copyright issues.
Steve leads a team with strong and specific experience in the life science intellectual property area, capable of and successful in handling massive, critical cases for clients. For more than two decades, he has been deeply engaged in legal work for the industry in areas of explosive growth, including antibody technology and cancer immunotherapy.
- Lead counsel for Boston Scientific in a series of patent and trade secret infringement litigations against Nevro Corp. in the District of Delaware relating to spinal cord stimulation technology. The cases involved affirmative patent and trade secret claims asserted by Boston Scientific, counterclaims for patent infringement asserted by Nevro, and parallel petitions for inter partes review in both directions before the PTAB. In a first trial, the jury returned a verdict finding Nevro liable for willful patent infringement and awarded Boston Scientific $20 million in damages. All matters settled favorably prior to two subsequent jury trials that were scheduled.
- Lead counsel for 3M Company, Merck & Co., Inc. and Merck, Sharp & Dohme Corp. in patent infringement suit filed by AptarGroup, Inc. relating to Merck’s Dulera® prescription asthma product. Achieved a complete victory whereby the asserted patents were invalidated in parallel IPRs and the complaint was dismissed with prejudice.
- Represented Bristol-Myers Squibb, Ono Pharmaceutical Co. and Nobel laureate Dr. Tasuku Honjo in patent litigation involving revolutionary immuno-oncology treatment methods. The team’s work contributed to a worldwide settlement that included an initial payment by defendant Merck & Co., Inc. of $625 million and payment of ongoing royalties through 2026.
- Lead counsel for Ethicon-Endo Surgery, a subsidiary of Johnson & Johnson, in an arbitration brought by EndoEvolution alleging trade secret misappropriation, breach of contract, fraud and breach of the implied covenant of good faith and fair dealing in connection with Ethicon’s launch of a new product. At stake were tens of millions of dollars in alleged damages and a potential injunction halting sales of a new product. Obtained complete victory for client on all claims.
- Lead counsel for Bristol-Myers Squibb, Ono Pharmaceutical Co. and Nobel laureate Dr. Tasuku Honjo in multiple patent infringement litigations against AstraZeneca related to anti-PD-L1 and anti-CTLA-4 antibodies. Succeeded in obtaining favorable settlement for all cases.
"Steve is an outstanding trial lawyer who understands the underlying business needs in litigation. He is terrific at oral arguments in court and is smart, conscientious and easy to work with."
Chambers USA, 2021
EducationJ.D., The George Washington University Law School, with honors, 1999
B.S., Pennsylvania State University, 1995
J.D., The George Washington University Law School, with honors, 1999
B.S., Pennsylvania State University, 1995
Bar AdmissionsPennsylvania
U.S. Patent and Trademark Office
Pennsylvania
U.S. Patent and Trademark Office
- BTI Consulting Group, Client Service All-Star, 2024.
- IAM, IAM Global Leaders, 2023-2024.
- Chambers USA, Leading Practitioner in Intellectual Property, 2017-2024; Described as a "phenomenal lawyer, held in high regard by his clients."
- Managing IP, Americas Managing IP Awards, Litigator of the Year for Pennsylvania, 2022.
- LMG Life Sciences, Leading Life Sciences Lawyer, 2021 and Life Sciences Star, 2022.
- The Legal Intelligencer, Pennsylvania Trailblazers, 2020.
- Best Lawyers in America, Lawyer of the Year, Litigation – Patent; Philadelphia, 2022.
- Best Lawyers in America, Litigation – Patent, 2013-2021.
- IAM Patent 1000, 2019-2021, 2024; Noted as “decisive and foresighted” with “superb lead counsel experience.” Also considered “brilliant at cross-examination.”
- The Legal 500 US, Patents: Litigation (Full Coverage), 2020-2024.
- The Legal 500 US, Patents: Litigation (International Trade Commission), 2020-2024.
- Managing Intellectual Property, IP Stars – Patent Star, 2019-2023.
- Philadelphia Business Journal, Best of the Bar Award, 2017.
- Law360, Top 10 Intellectual Property Lawyers under 40 to Watch in the United States, 2010.
- Volunteer lawyer, Support Center for Child Advocates.
- Adjunct professor, Patent Litigation, Temple University Beasley School of Law.
- “The Costs and Consequences of Determining Venue Post-Valeant v. Mylan: Coordinating Multiple ANDA Suits through MDLs,” ACI Paragraph IV Disputes, April 26, 2022.
- "Skinny Labeling Post-GSK v. Teva: How the Decision Will Inform Biosimilar Carve-Outs," ACI Summit on Biosimilars, June 22, 2021.
- "The Doctrine of Equivalents: Analyzing the Effects of Recent Federal Circuit Decisions on Litigation Strategies,” ACI Paragraph IV Disputes, October 6, 2020.
- “Trade Secrets for the Patent Litigator,” Federal Circuit Bar Association Bench & Bar Conference, June 16, 2020.
- “Getting Your (Patent) House in Order: Preparing for Biosimilar Challenges,” BIO IP Counsels Committee Conference, November 20, 2019.
- “Roundtable Discussion – Gene Therapy and Diagnosis Session,” International BioPharm IP Operations Conference (Nanjing, China), September 5, 2019.
- "A Question of Standing: Establishing the Right to Appeal a PTAB Decision,” ACI Summit on Biosimilars, June 24, 2019.
- "The BPCIA is Turning Ten: What's Next for Biosimilars?,” Biotechnology Industry Organization (BIO) Annual Meeting, June 3, 2019.
- “Patent and Competition Law,” Federal Circuit Bar Association—The Global Series 2018, April 29, 2018.
- “Economic Tools Used for Patent Damages Estimation,” Intellectual Property Owners Association Damages and Injunctions Committee Conference, June 7, 2017.
- “IPRs, CBMs, and the PTAB: Where Have We Been and Where are We Going?” Intellectual Property Owners Association annual meeting, September 13, 2016.
- “Current Developments and Strategies Relating to Divided Patent Infringement,” PBI Intellectual Property Law Institute, April 28, 2015.
- “Inter Partes Review: The First Eighteen Months,” Philadelphia Intellectual Property Law Association, March 19, 2014.